SCHEMBL525907

SCHEMBL525907

CCOC(=O)c1noc2c1CCc1cnc(SC)nc1-2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 2/20 0.46
CDK2 P24941 2/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PIM1 P11309 4/20 0.42
PIM2 Q9P1W9 4/20 0.42
TTK P33981 3/20 0.42
CDK4 P11802 1/20 0.41
CCND3 P30281 1/20 0.41
CCNA1 P78396 1/20 0.41
CDK6 Q00534 1/20 0.41
ALDH1A1 P00352 4/20 0.40
TDP1 Q9NUW8 2/20 0.40
POLB P06746 1/20 0.40
TDP2 O95551 2/20 0.39
SYK P43405 1/20 0.38
MAPT P10636 4/20 0.37
HPGD P15428 2/20 0.37
DUSP10 Q9Y6W6 1/20 0.37
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL526061 0.85 CCNA2 (0.47) CCNA2CDK2MEN1KMT2APIM1
SCHEMBL526125 0.83 TTK (0.52) CCNA2CDK2PIM1PIM2TTK
SCHEMBL9937086 0.79 CCNA2 (0.46) CCNA2CDK2MEN1KMT2APIM1
SCHEMBL4150790 0.79 CCNA2 (0.64) CCNA2CDK2MEN1KMT2APIM1
SCHEMBL10216355 0.76 CCNA2 (0.52) CCNA2CDK2MEN1KMT2APIM1
SCHEMBL25170969 0.76 TDP2 (0.57) CCNA2CDK2MEN1KMT2ACDK4
SCHEMBL31016026 0.76 TDP2 (0.57) CCNA2CDK2MEN1KMT2ACDK4
SCHEMBL9940556 0.75 PIM1 (0.55) CCNA2CDK2MEN1KMT2APIM1
SCHEMBL12466414 0.74 CCNA2 (0.46) CCNA2CDK2MEN1KMT2APIM1
SCHEMBL12698383 0.73 CCNA2 (0.57) CCNA2CDK2MEN1KMT2APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333205-B2 Isoxazolo-quinazolines as modulators of protein kinase activity NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-10 US disclosed
US-9333205-B2 Isoxazolo-quinazolines as modulators of protein kinase activity NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-10 US disclosed
US-9333205-B2 Isoxazolo-quinazolines as modulators of protein kinase activity NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-10 US disclosed
EP-2598508-B1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES SRL (IT) 2015-04-22 EP disclosed
EP-2598508-B1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES SRL (IT) 2015-04-22 EP disclosed
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-06-06 US disclosed
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-06-06 US disclosed
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-06-06 US disclosed
EP-2598508-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY Nerviano Medical Sciences S.r.l. (IT) 2013-06-05 EP disclosed
WO-2012013557-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-02 WO disclosed
WO-2012013557-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY CSNK1A1, RPS6KA1, CSNK2A1 CCNA2 3027/4885CDK2 406/4885MEN1 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.